Daiichi Sankyo Company, Limited Logo

Daiichi Sankyo Company, Limited

4568.T

(1.8)
Stock Price

4.953,00 JPY

6.2% ROA

12.09% ROE

58.54x PER

Market Cap.

7.919.221.411.185,00 JPY

7.18% DER

0.71% Yield

12.37% NPM

Daiichi Sankyo Company, Limited Stock Analysis

Daiichi Sankyo Company, Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Daiichi Sankyo Company, Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (12%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

ROE in an average range (7.63%) suggests satisfactory profitability and decent utilization of shareholders' equity.

3 ROA

The stock's ROA (5.37%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

5 Dividend

The company's track record of consistently paying dividends in the last three years highlights its dedication to providing investors with regular income.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (44.390) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (5.46x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Daiichi Sankyo Company, Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Daiichi Sankyo Company, Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Daiichi Sankyo Company, Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Daiichi Sankyo Company, Limited Revenue
Year Revenue Growth
1999 589.732.000.000
2000 545.072.000.000 -8.19%
2001 548.893.000.000 0.7%
2002 569.927.000.000 3.69%
2003 596.345.000.000 4.43%
2004 587.830.000.000 -1.45%
2005 925.918.000.000 36.51%
2006 929.507.000.000 0.39%
2007 880.120.000.000 -5.61%
2008 842.147.000.000 -4.51%
2009 952.105.000.000 11.55%
2010 967.365.000.000 1.58%
2011 938.677.000.000 -3.06%
2012 997.852.000.000 5.93%
2013 1.118.241.000.000 10.77%
2014 919.372.000.000 -21.63%
2015 986.446.000.000 6.8%
2016 955.124.000.000 -3.28%
2017 960.195.000.000 0.53%
2018 929.717.000.000 -3.28%
2019 981.793.000.000 5.3%
2020 962.516.000.000 -2%
2021 1.044.892.000.000 7.88%
2022 1.278.478.000.000 18.27%
2023 1.502.032.000.000 14.88%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Daiichi Sankyo Company, Limited Research and Development Expenses
Year Research and Development Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 158.716.000.000 100%
2006 170.662.000.000 7%
2007 163.472.000.000 -4.4%
2008 184.539.000.000 11.42%
2009 196.802.000.000 6.23%
2010 194.330.000.000 -1.27%
2011 185.052.000.000 -5.01%
2012 183.047.000.000 -1.1%
2013 191.212.000.000 4.27%
2014 190.666.000.000 -0.29%
2015 208.656.000.000 8.62%
2016 214.347.000.000 2.66%
2017 236.046.000.000 9.19%
2018 203.711.000.000 -15.87%
2019 197.465.000.000 -3.16%
2020 227.353.000.000 13.15%
2021 260.228.000.000 12.63%
2022 341.570.000.000 23.81%
2023 355.756.000.000 3.99%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Daiichi Sankyo Company, Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 212.235.000.000
2000 234.293.000.000 9.41%
2001 246.801.000.000 5.07%
2002 261.335.000.000 5.56%
2003 279.137.000.000 6.38%
2004 289.015.000.000 3.42%
2005 321.738.000.000 10.17%
2006 357.330.000.000 9.96%
2007 325.250.000.000 -9.86%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 413.187.000.000 100%
2014 331.195.000.000 -24.76%
2015 328.755.000.000 -0.74%
2016 302.475.000.000 -8.69%
2017 301.845.000.000 -0.21%
2018 277.695.000.000 -8.7%
2019 302.320.000.000 8.15%
2020 333.079.000.000 9.23%
2021 358.309.000.000 7.04%
2022 471.221.000.000 23.96%
2023 564.136.000.000 16.47%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Daiichi Sankyo Company, Limited EBITDA
Year EBITDA Growth
1999 142.713.000.000
2000 87.790.000.000 -62.56%
2001 80.650.000.000 -8.85%
2002 105.693.000.000 23.69%
2003 123.703.000.000 14.56%
2004 114.114.000.000 -8.4%
2005 203.163.000.000 43.83%
2006 251.076.000.000 19.08%
2007 199.415.000.000 -25.91%
2008 636.000.000.000 68.65%
2009 300.320.000.000 -111.77%
2010 329.730.000.000 8.92%
2011 323.312.000.000 -1.99%
2012 149.050.000.000 -116.92%
2013 178.189.000.000 16.35%
2014 125.119.000.000 -42.42%
2015 179.722.000.000 30.38%
2016 142.871.000.000 -25.79%
2017 131.924.000.000 -8.3%
2018 137.910.000.000 4.34%
2019 201.588.000.000 31.59%
2020 134.261.000.000 -50.15%
2021 137.514.000.000 2.37%
2022 203.123.000.000 32.3%
2023 281.148.000.000 27.75%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Daiichi Sankyo Company, Limited Gross Profit
Year Gross Profit Growth
1999 354.948.000.000
2000 322.083.000.000 -10.2%
2001 327.451.000.000 1.64%
2002 341.173.000.000 4.02%
2003 374.692.000.000 8.95%
2004 373.941.000.000 -0.2%
2005 635.182.000.000 41.13%
2006 664.306.000.000 4.38%
2007 645.549.000.000 -2.91%
2008 627.750.000.000 -2.84%
2009 674.074.000.000 6.87%
2010 685.688.000.000 1.69%
2011 670.068.000.000 -2.33%
2012 684.195.000.000 2.06%
2013 715.952.000.000 4.44%
2014 596.285.000.000 -20.07%
2015 667.824.000.000 10.71%
2016 605.751.000.000 -10.25%
2017 614.174.000.000 1.37%
2018 565.112.000.000 -8.68%
2019 638.587.000.000 11.51%
2020 624.227.000.000 -2.3%
2021 691.564.000.000 9.74%
2022 914.953.000.000 24.42%
2023 1.123.088.000.000 18.53%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Daiichi Sankyo Company, Limited Net Profit
Year Net Profit Growth
1999 42.817.000.000
2000 42.478.000.000 -0.8%
2001 38.795.000.000 -9.49%
2002 33.845.000.000 -14.63%
2003 43.411.000.000 22.04%
2004 48.282.000.000 10.09%
2005 87.693.000.000 44.94%
2006 78.550.000.000 -11.64%
2007 97.660.000.000 19.57%
2008 -215.499.000.000 145.32%
2009 41.852.000.000 614.91%
2010 70.121.000.000 40.31%
2011 10.383.000.000 -575.34%
2012 66.621.000.000 84.41%
2013 60.943.000.000 -9.32%
2014 322.119.000.000 81.08%
2015 82.282.000.000 -291.48%
2016 53.466.000.000 -53.9%
2017 60.282.000.000 11.31%
2018 93.409.000.000 35.46%
2019 129.074.000.000 27.63%
2020 75.958.000.000 -69.93%
2021 66.972.000.000 -13.42%
2022 109.188.000.000 38.66%
2023 159.972.000.000 31.75%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Daiichi Sankyo Company, Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 31
2000 31 0%
2001 29 -10.71%
2002 25 -12%
2003 33 21.88%
2004 37 13.51%
2005 40 5.13%
2006 36 -11.43%
2007 45 22.22%
2008 -101 144.55%
2009 20 631.58%
2010 33 42.42%
2011 5 -725%
2012 30 86.67%
2013 29 -7.14%
2014 153 81.58%
2015 40 -289.74%
2016 27 -50%
2017 30 13.33%
2018 48 37.5%
2019 66 27.27%
2020 39 -69.23%
2021 35 -14.71%
2022 57 39.29%
2023 83 32.53%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Daiichi Sankyo Company, Limited Free Cashflow
Year Free Cashflow Growth
2002 42.245.000.000
2003 22.351.000.000 -89.01%
2004 66.982.000.000 66.63%
2005 84.174.000.000 20.42%
2006 63.478.000.000 -32.6%
2007 15.081.000.000 -320.91%
2008 33.781.000.000 55.36%
2009 99.078.000.000 65.9%
2010 105.007.000.000 5.65%
2011 28.869.000.000 -263.74%
2012 50.385.000.000 42.7%
2013 -17.210.000.000 392.77%
2014 48.146.000.000 135.75%
2015 97.860.000.000 50.8%
2016 83.272.000.000 -17.52%
2017 70.431.000.000 -18.23%
2018 25.420.000.000 -177.07%
2019 144.036.000.000 82.35%
2020 128.114.000.000 -12.43%
2021 62.544.000.000 -104.84%
2022 47.148.000.000 -32.65%
2023 -40.889.000.000 215.31%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Daiichi Sankyo Company, Limited Operating Cashflow
Year Operating Cashflow Growth
2002 69.167.000.000
2003 71.207.000.000 2.86%
2004 96.703.000.000 26.37%
2005 132.760.000.000 27.16%
2006 106.430.000.000 -24.74%
2007 66.667.000.000 -59.64%
2008 78.383.000.000 14.95%
2009 130.235.000.000 39.81%
2010 141.139.000.000 7.73%
2011 92.569.000.000 -52.47%
2012 129.247.000.000 28.38%
2013 37.304.000.000 -246.47%
2014 142.776.000.000 73.87%
2015 174.281.000.000 18.08%
2016 136.234.000.000 -27.93%
2017 108.439.000.000 -25.63%
2018 92.033.000.000 -17.83%
2019 196.601.000.000 53.19%
2020 192.207.000.000 -2.29%
2021 139.226.000.000 -38.05%
2022 114.514.000.000 -21.58%
2023 -18.146.000.000 731.07%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Daiichi Sankyo Company, Limited Capital Expenditure
Year Capital Expenditure Growth
2002 26.922.000.000
2003 48.856.000.000 44.9%
2004 29.721.000.000 -64.38%
2005 48.586.000.000 38.83%
2006 42.952.000.000 -13.12%
2007 51.586.000.000 16.74%
2008 44.602.000.000 -15.66%
2009 31.157.000.000 -43.15%
2010 36.132.000.000 13.77%
2011 63.700.000.000 43.28%
2012 78.862.000.000 19.23%
2013 54.514.000.000 -44.66%
2014 94.630.000.000 42.39%
2015 76.421.000.000 -23.83%
2016 52.962.000.000 -44.29%
2017 38.008.000.000 -39.34%
2018 66.613.000.000 42.94%
2019 52.565.000.000 -26.73%
2020 64.093.000.000 17.99%
2021 76.682.000.000 16.42%
2022 67.366.000.000 -13.83%
2023 22.743.000.000 -196.21%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Daiichi Sankyo Company, Limited Equity
Year Equity Growth
1999 615.011.000.000
2000 668.318.000.000 7.98%
2001 652.220.000.000 -2.47%
2002 658.707.000.000 0.98%
2003 682.594.000.000 3.5%
2004 716.587.000.000 4.74%
2005 1.237.529.000.000 42.1%
2006 1.268.657.000.000 2.45%
2007 1.244.135.000.000 -1.97%
2008 865.442.000.000 -43.76%
2009 859.002.000.000 -0.75%
2010 852.549.000.000 -0.76%
2011 808.437.000.000 -5.46%
2012 886.733.000.000 8.83%
2013 979.933.000.000 9.51%
2014 1.304.057.000.000 24.86%
2015 1.231.406.000.000 -5.9%
2016 1.175.897.000.000 -4.72%
2017 1.133.040.000.000 -3.78%
2018 1.249.704.000.000 9.34%
2019 1.306.273.000.000 4.33%
2020 1.272.053.000.000 -2.69%
2021 1.350.872.000.000 5.83%
2022 1.445.854.000.000 6.57%
2023 1.594.002.000.000 9.29%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Daiichi Sankyo Company, Limited Assets
Year Assets Growth
1999 921.662.000.000
2000 964.902.000.000 4.48%
2001 916.305.000.000 -5.3%
2002 915.792.000.000 -0.06%
2003 927.244.000.000 1.24%
2004 976.230.000.000 5.02%
2005 1.596.127.000.000 38.84%
2006 1.636.835.000.000 2.49%
2007 1.487.889.000.000 -10.01%
2008 1.494.599.000.000 0.45%
2009 1.489.510.000.000 -0.34%
2010 1.480.240.000.000 -0.63%
2011 1.518.479.000.000 2.52%
2012 1.644.071.000.000 7.64%
2013 1.854.037.000.000 11.32%
2014 1.982.286.000.000 6.47%
2015 1.900.522.000.000 -4.3%
2016 1.914.979.000.000 0.75%
2017 1.897.754.000.000 -0.91%
2018 2.088.051.000.000 9.11%
2019 2.105.619.000.000 0.83%
2020 2.085.178.000.000 -0.98%
2021 2.221.402.000.000 6.13%
2022 2.508.889.000.000 11.46%
2023 2.649.101.000.000 5.29%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Daiichi Sankyo Company, Limited Liabilities
Year Liabilities Growth
1999 0
2000 0 0%
2001 0 0%
2002 248.704.000.000 100%
2003 235.807.000.000 -5.47%
2004 250.209.000.000 5.76%
2005 346.988.000.000 27.89%
2006 364.687.000.000 4.85%
2007 242.998.000.000 -50.08%
2008 605.982.000.000 59.9%
2009 600.002.000.000 -1%
2010 592.538.000.000 -1.26%
2011 685.730.000.000 13.59%
2012 728.328.000.000 5.85%
2013 846.510.000.000 13.96%
2014 675.245.000.000 -25.36%
2015 667.001.000.000 -1.24%
2016 743.551.000.000 10.3%
2017 764.713.000.000 2.77%
2018 838.346.000.000 8.78%
2019 799.345.000.000 -4.88%
2020 813.125.000.000 1.69%
2021 870.530.000.000 6.59%
2022 1.063.035.000.000 18.11%
2023 1.055.099.000.000 -0.75%

Daiichi Sankyo Company, Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
728.59
Net Income per Share
77.13
Price to Earning Ratio
58.54x
Price To Sales Ratio
5.67x
POCF Ratio
2150.86
PFCF Ratio
-99.51
Price to Book Ratio
5.43
EV to Sales
5.33
EV Over EBITDA
35.01
EV to Operating CashFlow
1849.15
EV to FreeCashFlow
-93.53
Earnings Yield
0.02
FreeCashFlow Yield
-0.01
Market Cap
7.919,22 Bil.
Enterprise Value
7.442,83 Bil.
Graham Number
1201.1
Graham NetNet
64.76

Income Statement Metrics

Net Income per Share
77.13
Income Quality
0.03
ROE
0.1
Return On Assets
0.06
Return On Capital Employed
0.07
Net Income per EBT
0.93
EBT Per Ebit
1.06
Ebit per Revenue
0.13
Effective Tax Rate
0.06

Margins

Sales, General, & Administrative to Revenue
0.39
Research & Developement to Revenue
0.26
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.72
Operating Profit Margin
0.13
Pretax Profit Margin
0.13
Net Profit Margin
0.12

Dividends

Dividend Yield
0.01
Dividend Yield %
0.71
Payout Ratio
0.39
Dividend Per Share
32

Operating Metrics

Operating Cashflow per Share
2.1
Free CashFlow per Share
-41.5
Capex to Operating CashFlow
-20.77
Capex to Revenue
-0.06
Capex to Depreciation
-1.26
Return on Invested Capital
0.08
Return on Tangible Assets
0.06
Days Sales Outstanding
112.22
Days Payables Outstanding
435.5
Days of Inventory on Hand
351.29
Receivables Turnover
3.25
Payables Turnover
0.84
Inventory Turnover
1.04
Capex per Share
-43.6

Balance Sheet

Cash per Share
348,54
Book Value per Share
831,32
Tangible Book Value per Share
694.04
Shareholders Equity per Share
831.32
Interest Debt per Share
64.12
Debt to Equity
0.07
Debt to Assets
0.04
Net Debt to EBITDA
-2.24
Current Ratio
2.86
Tangible Asset Value
1.330,77 Bil.
Net Current Asset Value
468,63 Bil.
Invested Capital
0.07
Working Capital
991,48 Bil.
Intangibles to Total Assets
0.1
Average Receivables
418,98 Bil.
Average Payables
449,77 Bil.
Average Inventory
358453000000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Daiichi Sankyo Company, Limited Dividends
Year Dividends Growth
2000 25
2001 15 -71.43%
2002 15 6.67%
2003 5 -200%
2004 23 77.27%
2006 55 60%
2007 65 15.38%
2008 75 13.33%
2009 70 -7.14%
2010 60 -16.67%
2011 60 0%
2012 60 0%
2013 60 0%
2014 60 0%
2015 40 -50%
2016 65 38.46%
2017 70 7.14%
2018 70 0%
2019 70 0%
2020 157 55.13%
2021 27 -477.78%
2022 27 0%
2023 32 15.63%
2024 0 0%

Daiichi Sankyo Company, Limited Profile

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

CEO
Mr. Sunao Manabe D.V.M., Ph.D
Employee
17.435
Address
3-5-1, Nihonbashi-honcho
Tokyo, 103-8426

Daiichi Sankyo Company, Limited Executives & BODs

Daiichi Sankyo Company, Limited Executives & BODs
# Name Age
1 Ms. Marielle Cohard-Radice M.D.
Global Head of Development
70
2 Mr. Hiroyuki Okuzawa
President, Chief Operating Officer & Representative Director
70
3 Mr. Masahiko Ohtsuki
Senior Managing Executive Officer, Head of Global DX, Chief Digital Transformation Officer & Director
70
4 Dr. Shoji Hirashima
Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director
70
5 Hiroto Kashiwase
Managing Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQ
70
6 Akio Sakurai
Corporate Officer, Head of Sales and Marketing Div. & Japan Business Unit
70
7 Kentaro Asakura
Vice President of Corporate Communications Department
70
8 Mr. Koji Ogawa
Managing Executive Officer, Head of Global Corporate Planning & Management and Chief Financial Officer
70
9 Mr. Sunao Manabe D.V.M., Ph.D.
Group Chief Executive Officer & Executive Chairperson
70
10 Naoto Tsukaguchi
Gen. Counsel, Corporation Officer, Head of Global Leg., IP, Global Compl. and Risk & Vice President of Leg. Aff. Dept.
70

Daiichi Sankyo Company, Limited Competitors